In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line

Y. Naganawa, K. Ohsugi, R. Kase, Isao Date, H. Sakuraba, N. Sakuragawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galactosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant human α-gal produced in CHO cells or in human fibroblasts is currently being evaluated in clinical trials as a potential therapy for this disease. However, it requires lifelong therapy involving a large amount of purified α-gal. As a novel approach for treatment of Fabry disease we used polymer encapsulated Chinese hamster ovary (CHO) cells genetically modified to express α-gal. The secreted high levels of α-gal passed through the semipermeable polymeric membrane. Using coculture system with Fabry fibroblasts, the secreted enzyme was taken up in cells, resulting in reduced accumulation of CTH in Fabry fibroblasts. This in vitro study demonstrated that an encapsulated α-gal-secreting cell line can be used to treat Fabry mice by transplantation in vivo. Judging from the protection against immune rejection by a semipermeable synthetic membrane, this novel approach may be applied to treat patients with Fabry disease and other lysosomal storage diseases.

Original languageEnglish
Pages (from-to)325-329
Number of pages5
JournalCell Transplantation
Volume11
Issue number4
Publication statusPublished - 2002

Fingerprint

Fabry Disease
Cricetulus
Encapsulation
Ovary
Fibroblasts
Cells
Cell Line
Ceramides
Enzymes
Galactosidases
Lysosomal Storage Diseases
Membranes
Hydrolases
Coculture Techniques
Polymers
Therapeutics
Transplantation
Polymeric membranes
Clinical Trials
In Vitro Techniques

Keywords

  • α-Galactosidase
  • Ceramide trihexoside (CTH)
  • CHO cells
  • Encapsulation
  • Fabry disease
  • Fibroblasts
  • Gene therapy

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation

Cite this

Naganawa, Y., Ohsugi, K., Kase, R., Date, I., Sakuraba, H., & Sakuragawa, N. (2002). In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line. Cell Transplantation, 11(4), 325-329.

In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line. / Naganawa, Y.; Ohsugi, K.; Kase, R.; Date, Isao; Sakuraba, H.; Sakuragawa, N.

In: Cell Transplantation, Vol. 11, No. 4, 2002, p. 325-329.

Research output: Contribution to journalArticle

Naganawa, Y, Ohsugi, K, Kase, R, Date, I, Sakuraba, H & Sakuragawa, N 2002, 'In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line', Cell Transplantation, vol. 11, no. 4, pp. 325-329.
Naganawa, Y. ; Ohsugi, K. ; Kase, R. ; Date, Isao ; Sakuraba, H. ; Sakuragawa, N. / In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line. In: Cell Transplantation. 2002 ; Vol. 11, No. 4. pp. 325-329.
@article{7d85d8eec12345a2ab6e332fd15ef660,
title = "In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line",
abstract = "Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galactosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant human α-gal produced in CHO cells or in human fibroblasts is currently being evaluated in clinical trials as a potential therapy for this disease. However, it requires lifelong therapy involving a large amount of purified α-gal. As a novel approach for treatment of Fabry disease we used polymer encapsulated Chinese hamster ovary (CHO) cells genetically modified to express α-gal. The secreted high levels of α-gal passed through the semipermeable polymeric membrane. Using coculture system with Fabry fibroblasts, the secreted enzyme was taken up in cells, resulting in reduced accumulation of CTH in Fabry fibroblasts. This in vitro study demonstrated that an encapsulated α-gal-secreting cell line can be used to treat Fabry mice by transplantation in vivo. Judging from the protection against immune rejection by a semipermeable synthetic membrane, this novel approach may be applied to treat patients with Fabry disease and other lysosomal storage diseases.",
keywords = "α-Galactosidase, Ceramide trihexoside (CTH), CHO cells, Encapsulation, Fabry disease, Fibroblasts, Gene therapy",
author = "Y. Naganawa and K. Ohsugi and R. Kase and Isao Date and H. Sakuraba and N. Sakuragawa",
year = "2002",
language = "English",
volume = "11",
pages = "325--329",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "4",

}

TY - JOUR

T1 - In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line

AU - Naganawa, Y.

AU - Ohsugi, K.

AU - Kase, R.

AU - Date, Isao

AU - Sakuraba, H.

AU - Sakuragawa, N.

PY - 2002

Y1 - 2002

N2 - Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galactosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant human α-gal produced in CHO cells or in human fibroblasts is currently being evaluated in clinical trials as a potential therapy for this disease. However, it requires lifelong therapy involving a large amount of purified α-gal. As a novel approach for treatment of Fabry disease we used polymer encapsulated Chinese hamster ovary (CHO) cells genetically modified to express α-gal. The secreted high levels of α-gal passed through the semipermeable polymeric membrane. Using coculture system with Fabry fibroblasts, the secreted enzyme was taken up in cells, resulting in reduced accumulation of CTH in Fabry fibroblasts. This in vitro study demonstrated that an encapsulated α-gal-secreting cell line can be used to treat Fabry mice by transplantation in vivo. Judging from the protection against immune rejection by a semipermeable synthetic membrane, this novel approach may be applied to treat patients with Fabry disease and other lysosomal storage diseases.

AB - Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galactosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant human α-gal produced in CHO cells or in human fibroblasts is currently being evaluated in clinical trials as a potential therapy for this disease. However, it requires lifelong therapy involving a large amount of purified α-gal. As a novel approach for treatment of Fabry disease we used polymer encapsulated Chinese hamster ovary (CHO) cells genetically modified to express α-gal. The secreted high levels of α-gal passed through the semipermeable polymeric membrane. Using coculture system with Fabry fibroblasts, the secreted enzyme was taken up in cells, resulting in reduced accumulation of CTH in Fabry fibroblasts. This in vitro study demonstrated that an encapsulated α-gal-secreting cell line can be used to treat Fabry mice by transplantation in vivo. Judging from the protection against immune rejection by a semipermeable synthetic membrane, this novel approach may be applied to treat patients with Fabry disease and other lysosomal storage diseases.

KW - α-Galactosidase

KW - Ceramide trihexoside (CTH)

KW - CHO cells

KW - Encapsulation

KW - Fabry disease

KW - Fibroblasts

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0036023226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036023226&partnerID=8YFLogxK

M3 - Article

C2 - 12162373

AN - SCOPUS:0036023226

VL - 11

SP - 325

EP - 329

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 4

ER -